Tarsus Q3 2024: XDEMVY sales $48.1M, net loss narrows to $23.4M

Tarsus Pharmaceuticals, Inc.

2024-Q3 EPS reported -$2.48 revenue$116,545,000

Net product sales of $48.1M in Q3 2024, up from $1.7M in Q3 2023; over 41,400 bottles delivered.
Net loss of $23.4M ($0.61 per share) compared to $39.1M ($1.28 per share) in Q3 2023.
Secured the two remaining large Medicare contracts; coverage now extends to >80% of covered lives.
Appointed Elizabeth Yeu, M.D. as Chief Medical Officer and Katherine Goodrich, M.D. to board.
Cash and marketable securities of $317.0M as of September 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.